Zanvastro (zilganersen-alexander) Intrathecal Injection: First Targeted Therapy for Alexander Disease

　　1.Overview and Mechanism

　　Zanvastro(zilganersen-alexander),developed by Ionis Pharmaceuticals,is the first disease-modifying therapy for Alexander disease(AxD),approved by the US FDA on September 3,2026.It received orphan drug,rare pediatric disease,breakthrough therapy,and fast track designations.

　　As a second-generation chemically modified antisense oligonucleotide(ASO),Zanvastro precisely targets pathogenic GFAP gene mRNA,degrading abnormal transcripts to inhibit overproduction of toxic glial fibrillary acidic protein.This blocks abnormal protein accumulation at the source,reduces astrocyte damage,and slows white matter progression.Administered intrathecally,it bypasses the blood-brain barrier,directly acting on the central nervous system,with dosing every 12 weeks(3 months)for long-term efficacy.

　　2.Disease Background and Indication

　　Alexander disease is a rare autosomal dominant leukodystrophy caused by GFAP mutations,leading to protein accumulation,demyelination,and neuronal apoptosis.It presents as infantile,juvenile,or adult-onset,with symptoms like developmental regression,gait abnormality,ataxia,seizures,and dysphagia.Previously,only symptomatic care was available.

　　Zanvastro is indicated for all-age(adult and pediatric)patients with genetically confirmed GFAP mutation and progressive neurological impairment.It is the only targeted treatment that modifies disease course.

　　3.Clinical Trial Data and Efficacy

　　Approval was based on a global phaseⅠ/Ⅱ/Ⅲseamless trial(NCT04849741)enrolling 54 patients aged 1.5–53 years,randomized 2:1 to receive 50 mg intrathecal injection every 12 weeks for 60 weeks double-blind.

　　In patients over 5 years with walking impairment,treatment significantly stabilized walking speed and reduced functional decline versus control.In children aged 2–4,gross motor function scores were superior,preventing developmental regression.Plasma GFAP biomarker levels dropped significantly.Overall safety was manageable with no new severe toxicities.

　　4.Dosing and Safety Warnings

　　Recommended dose:50 mg every 12 weeks via lumbar puncture by a specialist.Not for intravenous or oral use.Common adverse reactions:post-lumbar puncture headache,back pain,low fever,vomiting,usually mild to moderate and self-resolving.Key warning:risk of aseptic meningitis;monitor temperature,consciousness,and meningeal signs post-dose.Contraception advised for women of childbearing potential;long-term follow-up needed for infants.

　　5.Clinical Innovation

　　Zanvastro ends the century-long lack of targeted therapy for Alexander disease.As the first GFAP-targeted ASO neuro-drug,its central precision and long-acting regimen reduce treatment burden,setting a new paradigm for rare neurological genetic disorders.